TCM
RARE icon

Timpani Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Timpani Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32,235
Closed -$2.46M – 96
2018
Q3 		$2.46M Buy
+32,235
New +$2.62M 0.71% 57

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Timpani Capital Management's RARE Position: Q4 2018 in Review

Timpani Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 32,235 shares — an estimated $2.46M sold.

Timpani Capital Management first reported a position in RARE in Q3 2018 and held it in 1 quarter. The position peaked at $2.46M in Q3 2018. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

  • Timpani Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Timpani Capital Management sold 32,235 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $2.46M.
  • Timpani Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 1 quarter.
  • Timpani Capital Management's Ultragenyx Pharmaceutical position peaked at $2.46M in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Timpani Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.